MASI vs. LIVN, CNMD, INMD, NTUS, BLFS, STE, HOLX, BAX, PODD, and TFX
Should you be buying Masimo stock or one of its competitors? The main competitors of Masimo include LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Natus Medical (NTUS), BioLife Solutions (BLFS), STERIS (STE), Hologic (HOLX), Baxter International (BAX), Insulet (PODD), and Teleflex (TFX). These companies are all part of the "medical" sector.
Masimo (NASDAQ:MASI) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.
In the previous week, Masimo had 5 more articles in the media than LivaNova. MarketBeat recorded 17 mentions for Masimo and 12 mentions for LivaNova. LivaNova's average media sentiment score of 0.71 beat Masimo's score of 0.66 indicating that LivaNova is being referred to more favorably in the news media.
Masimo has a net margin of 4.01% compared to LivaNova's net margin of -2.68%. LivaNova's return on equity of 13.59% beat Masimo's return on equity.
Masimo presently has a consensus price target of $143.57, suggesting a potential upside of 14.44%. LivaNova has a consensus price target of $66.20, suggesting a potential upside of 24.02%. Given LivaNova's higher possible upside, analysts clearly believe LivaNova is more favorable than Masimo.
Masimo has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, LivaNova has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.
86.0% of Masimo shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Masimo has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
Masimo received 73 more outperform votes than LivaNova when rated by MarketBeat users. However, 68.84% of users gave LivaNova an outperform vote while only 63.89% of users gave Masimo an outperform vote.
Summary
Masimo beats LivaNova on 12 of the 18 factors compared between the two stocks.
Get Masimo News Delivered to You Automatically
Sign up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
